Evidence map›Paper›PMID 24683506›Full record

ReviewBrain and behavior2014

N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.

Reza Bavarsad Shahripour, Mark R Harrigan, Andrei V Alexandrov

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Brain and behavior, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04562597 (A Pilot Trial to Determine the Effective Dose of N-acetylcysteine for Opioid Reduction in Patients Undergoing Spine Surgery.), which is not on this map. Cited by 207 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
207citing papers in PubMed, 5 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04562597 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

A Pilot Trial to Determine the Effective Dose of N-acetylcysteine for Opioid Reduction in Patients Undergoing Spine Surgery.

TypeinterventionalSponsorMedical University of South CarolinaRan2021 to 2022Enrolled50ConditionsSurgeryArmsDose Response Curve Placebo, Dose Response Curve N-acetylcysteine 50 mg/kg, Dose Response Curve N-acetylcysteine 100 mg/kg, Dose Response Curve N-acetylcysteine 150 mg/kg, Opioid Reduction with Optimal N-acetylcysteine Dose
3 · Its place in the literature

Who cites it

207 citing papers in PubMed, 5 syntheses or guidelines pooled it, 399 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Assessment of Renal and Hepatic Tissue-Protective Effects of N-Acetylcysteine via Ammonia Metabolism: A Prospective Randomized Study.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Trial
  15. Amelioration of oxidative stress using N-acetylcysteine in canine parvoviral enteritis.Journal of veterinary pharmacology and therapeutics · 2018
    Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Review

147 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Reza Bavarsad ShahripourDepartment of Neurology, Comprehensive Stroke Center, University of Alabama Birmingham, Alabama.
Mark R HarriganDepartment of Surgery, Division of Neurosurgery, University of Alabama Birmingham, Alabama.
Andrei V AlexandrovDepartment of Neurology, Comprehensive Stroke Center, University of Alabama Birmingham, Alabama.
University of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is an expanding field of research investigating the benefits of medicines with multiple mechanisms of action across neurological disorders. N-acetylcysteine (NAC), widely known as an antidote to acetaminophen overdose, is now emerging as treatment of vascular and nonvascular neurological disorders. NAC as a precursor to the antioxidant glutathione modulates glutamatergic, neurotrophic, and inflammatory pathways. AIM AND DISCUSSION: Most NAC studies up to date have been carried out in animal models of various neurological disorders with only a few studies completed in humans. In psychiatry, NAC has been tested in over 20 clinical trials as an adjunctive treatment; however, this topic is beyond the scope of this review. Herein, we discuss NAC molecular, intracellular, and systemic effects, focusing on its potential applications in neurodegenerative diseases including spinocerebellar ataxia, Parkinson's disease, tardive dyskinesia, myoclonus epilepsy of the Unverricht-Lundbor type as well as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease.

conclusionFinally, we review the potential applications of NAC to facilitate recovery after traumatic brain injury, cerebral ischemia, and in treatment of cerebrovascular vasospasm after subarachnoid hemorrhage.

Indexed as

AcetylcysteineAnimalsFree Radical ScavengersHumansNervous System DiseasesAcetylcysteineFree Radical ScavengersN-acetylcysteineneurological disordertreatment

Identifiers

PMID24683506
PMCPMC3967529
OpenAlexW2123739790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.